Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C9H11NO2 |
| Molecular Weight | 165.1891 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](CC1=CC=CC=C1)C(O)=O
InChI
InChIKey=COLNVLDHVKWLRT-QMMMGPOBSA-N
InChI=1S/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/t8-/m0/s1
| Molecular Formula | C9H11NO2 |
| Molecular Weight | 165.1891 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Phenylalanine is a biologically essential amino acid that acts as a precursor to tyrosine and the catecholamines (epinephrine, norepinephrine, dopamine, and tyramine), and is a constituent
of many central nervous system neuropeptides. Normal dietary levels of phenylalanine are approximately 1-2 grams daily. Phenylalanine appears in two forms which are identical mirror images of each other: L-phenylalanine, a nutritional supplement, and D-phenylalanine, an effective painkiller and antidepressant due to its ability to inhibit the breakdown of enkephalins, the brain’s natural pain killers.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL3076 |
|||
Target ID: CHEMBL1907608 |
1.71 mM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | FREAMINE III 10% Approved UseParenteral nutrition with 8.5% FreAmine® III (Amino Acid Injection) with Electrolytes is
indicated to prevent nitrogen loss or treat negative nitrogen balance in adults and pediatric
patients, where (1) the alimentary tract, by the oral, gastrostomy, or jejunostomy route, cannot or
should not be used, or adequate protein intake is not feasible by these routes; (2) gastrointestinal
absorption of protein is impaired; or (3) protein requirements are substantially increased as with
extensive burns. Dosage, route of administration, and concomitant infusion of non-protein
calories are dependent on various factors, such as nutritional metabolic status of the patient, anticipated duration of parenteral nutritional support, and vein tolerance Launch Date1971 |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1389 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11244252/ |
20 mg/kg single, intravenous dose: 20 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
PHENYLALANINE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
35.7 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11244252/ |
20 mg/kg single, intravenous dose: 20 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
PHENYLALANINE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11244252/ |
20 mg/kg single, intravenous dose: 20 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
PHENYLALANINE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Activation of BMK1 via tyrosine 1062 in RET by GDNF and MEN2A mutation. | 2001-03-02 |
|
| Tight control of exogenous SERCA expression is required to obtain acceleration of calcium transients with minimal cytotoxic effects in cardiac myocytes. | 2001-03-02 |
|
| Detection of hydroxyl radicals by D-phenylalanine hydroxylation: a specific assay for hydroxyl radical generation in biological systems. | 2001-03-01 |
|
| Spectral and metal-binding properties of three single-point tryptophan mutants of the human transferrin N-lobe. | 2001-03-01 |
|
| Plasma free amino acid concentrations in healthy Guatemalan adults and in patients with classic dengue. | 2001-03 |
|
| Binding diversity of a noncovalent-type low-molecular-weight serine protease inhibitor and function of a catalytic water molecule: X-ray crystal structure of PKSI-527--inhibited trypsin. | 2001-03 |
|
| Combined pituitary hormone deficiency due to the F135C human Pit-1 (pituitary-specific factor 1) gene mutation: functional and structural correlates. | 2001-03 |
|
| Ligand migration in human myoglobin: steric effects of isoleucine 107(G8) on O(2) and CO binding. | 2001-03 |
|
| Acute effects of peritoneal dialysis with dialysates containing dextrose or dextrose and amino acids on muscle protein turnover in patients with chronic renal failure. | 2001-03 |
|
| Selected Contribution: IGF-I antibody prevents increases in protein synthesis in epitrochlearis muscles from refed, diabetic rats. | 2001-03 |
|
| A possible role for metalloproteinases in renal cyst development. | 2001-03 |
|
| Complete loss of P/Q calcium channel activity caused by a CACNA1A missense mutation carried by patients with episodic ataxia type 2. | 2001-03 |
|
| Occurrence of D-Amino Acids and a pyridoxal 5'-phosphate-dependent aspartate racemase in the acidothermophilic archaeon, Thermoplasma acidophilum. | 2001-02-23 |
|
| Cloning of dopamine, norepinephrine and serotonin transporters from monkey brain: relevance to cocaine sensitivity. | 2001-02-19 |
|
| FDA approves nateglinide for treatment of type 2 diabetes. | 2001-02-15 |
|
| Antioxidant alpha-lipoic acid and protein turnover in insulin-resistant rat muscle. | 2001-02-15 |
|
| Kynurenine aminotransferase I activity in human placenta. | 2001-02-15 |
|
| Altered mitochondrial gene expression in human gestational trophoblastic diseases. | 2001-02-15 |
|
| Enkephalin analogues with 2',6'-dimethylphenylalanine replacing phenylalanine in position 4. | 2001-02-12 |
|
| Enhancement, relaxation, and reversal of the stereoselectivity for phosphotriesterase by rational evolution of active site residues. | 2001-02-06 |
|
| Effects of the potent analgesic enkephalin-catabolizing enzyme inhibitors RB101 and kelatorphan on respiration. | 2001-02-01 |
|
| Development of procedures for determining the amino acid requirements of chickens by the indicator amino acid oxidation method. | 2001-02 |
|
| Detection and typing of human papillomavirus in anal epidermoid carcinomas: sequence variation in the E7 gene of human papillomavirus Type 16. | 2001-02 |
|
| Comparison of in vitro systems of protein digestion using either mammal or fish proteolytic enzymes. | 2001-02 |
|
| Mutation analysis of phenylketonuria in Yamagata prefecture, Japan. | 2001-02 |
|
| Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter. | 2001-02 |
|
| Auto-inhibition of Ca(2+)/calmodulin-dependent protein kinase II by its ATP-binding domain. | 2001-02 |
|
| Mutations of the phenylalanine hydroxylase (PAH) gene in Brazilian patients with phenylketonuria. | 2001-02 |
|
| A comparison of kinetic and regulatory properties of the tetrameric and dimeric forms of wild-type and Thr427-->Pro mutant human phenylalanine hydroxylase: contribution of the flexible hinge region Asp425-Gln429 to the tetramerization and cooperative substrate binding. | 2001-02 |
|
| Pumping capacity of bacterial reaction centers and backpressure regulation of energy transduction. | 2001-02 |
|
| Design, X-ray crystallography, molecular modelling and thermal stability studies of mutant enzymes at site 172 of 3-isopropylmalate dehydrogenase from Thermus thermophilus. | 2001-02 |
|
| [A study of phenylketonuria heterozygotes screening in married population of Tianjin area]. | 2001-02 |
|
| Tyrosine phosphorylation of p120(ctn) in v-Src transfected L cells depends on its association with E-cadherin and reduces adhesion activity. | 2001-02 |
|
| In vivo protein synthetic rates of atrial, ventricular, and pulmonary tissue proteins in aortic constriction, goldblatt, and bromoethylamine models of hypertension. | 2001-02 |
|
| Aldehyde dehydrogenase. Maintaining critical active site geometry at motif 8 in the class 3 enzyme. | 2001-02 |
|
| Molecular engineering of myoglobin: the improvement of oxidation activity by replacing Phe-43 with tryptophan. | 2001-01-30 |
|
| Essential role of the N-terminal autoregulatory sequence in the regulation of phenylalanine hydroxylase. | 2001-01-19 |
|
| Amino acid phosphoramidate monoesters of 3'-azido-3'-deoxythymidine: relationship between antiviral potency and intracellular metabolism. | 2001-01-18 |
|
| Development and de novo protein synthetic activity of bovine embryos produced in vitro in different culture systems. | 2001-01-15 |
|
| Biological properties of Phe(o)-opioid peptide analogues. | 2001-01-12 |
|
| [Fasting blood glucose has little value. Postprandial glucose indicates risk]. | 2001-01-11 |
|
| The suppressive effect of dietary restriction and weight loss in the obese on the generation of reactive oxygen species by leukocytes, lipid peroxidation, and protein carbonylation. | 2001-01 |
|
| Three new mutations in the gene for the growth hormone (gh)-releasing hormone receptor in familial isolated gh deficiency type ib. | 2001-01 |
|
| A silent mutation induces exon skipping in the phenylalanine hydroxylase gene in phenylketonuria. | 2001-01 |
|
| N-(Hydroxyaminocarbonyl)phenylalanine: a novel class of inhibitor for carboxypeptidase A. | 2001-01 |
|
| Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo. | 2001-01 |
|
| Physical stability of the blue pigments formed from geniposide of gardenia fruits: effects of pH, temperature, and light. | 2001-01 |
|
| New analogues of bradykinin containing a conformationally restricted dipeptide fragment in their molecules. | 2001-01 |
|
| Epidermal H(2)O(2) accumulation alters tetrahydrobiopterin (6BH4) recycling in vitiligo: identification of a general mechanism in regulation of all 6BH4-dependent processes? | 2001-01 |
|
| A matrix metalloproteinase inhibitor, batimastat, retards the development of osteolytic bone metastases by MDA-MB-231 human breast cancer cells in Balb C nu/nu mice. | 2001-01 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.cpmedical.net/pdf/Phenylalanine.pdf
L-Phenylalanine Capsules (400 mg/cap): one to two capsules per day on an empty stomach.
L-Phenylalanine Powder: 480 mg one to two times per day on an empty stomach.
DL-Phenylalanine Capsules (500 mg/cap): one capsule daily on an empty stomach.
DL-Phenylalanine Powder: 1/8 level teaspoon two to three times daily on an empty stomach.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11986979
In cultured hippocampal neurons from newborn rats L-phenylalanine specifically and reversibly attenuated NMDA-activated currents in a concentration-dependent manner (IC50=1.71 mM)
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:46:29 GMT 2025
by
admin
on
Mon Mar 31 17:46:29 GMT 2025
|
| Record UNII |
47E5O17Y3R
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
LOINC |
53396-8
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
53151-7
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
13893-3
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
53398-4
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
29573-3
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
74481-3
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
CFR |
21 CFR 201.21
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
53157-4
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
27362-3
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
47981-6
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
32263-6
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
55970-8
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
47724-0
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
26981-1
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
14875-9
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
JECFA EVALUATION |
L-PHENYLALANINE
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
47721-6
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
30055-8
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
25970-5
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
44349-9
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
53156-6
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
12803-3
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
26967-0
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
22646-4
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
2764-9
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
20653-2
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
41170-2
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
22683-7
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
49484-9
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
DSLD |
1580 (Number of products:829)
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
2763-1
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
2766-4
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
32265-1
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
53394-3
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
DSLD |
169 (Number of products:17)
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
47722-4
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
38495-8
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
2762-3
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
25495-3
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
57995-3
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
47725-7
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
44348-1
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
13409-8
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
21057-5
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
NCI_THESAURUS |
C68442
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
53153-3
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
21056-7
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
75268-3
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
35572-7
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
47723-2
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
29571-7
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
55969-0
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
25969-7
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
CFR |
21 CFR 172.320
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
22737-1
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
CFR |
21 CFR 201.66
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
32264-4
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
53392-7
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
18475-4
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
2768-0
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
53393-5
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
2767-2
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
29572-5
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
||
|
LOINC |
2765-6
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1825
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
PRIMARY | |||
|
2144
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
PRIMARY | |||
|
200-568-1
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
PRIMARY | |||
|
C29601
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
PRIMARY | |||
|
1418
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
PRIMARY | |||
|
D010649
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
PRIMARY | |||
|
6140
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
PRIMARY | |||
|
6168
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
PRIMARY | |||
|
58095
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
PRIMARY | |||
|
100000092416
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
PRIMARY | |||
|
47E5O17Y3R
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
PRIMARY | |||
|
CHEMBL301523
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
PRIMARY | |||
|
63-91-2
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
PRIMARY | |||
|
29997
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
PRIMARY | |||
|
DB00120
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
PRIMARY | |||
|
8156
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB32327
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
PRIMARY | |||
|
SUB09786MIG
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
PRIMARY | |||
|
79477
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
PRIMARY | |||
|
PHENYLALANINE
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
PRIMARY | |||
|
1530503
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
PRIMARY | |||
|
17295
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
PRIMARY | |||
|
47E5O17Y3R
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
PRIMARY | |||
|
m8652
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
PRIMARY | Merck Index | ||
|
28044
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
PRIMARY | |||
|
DTXSID4040763
Created by
admin on Mon Mar 31 17:46:29 GMT 2025 , Edited by admin on Mon Mar 31 17:46:29 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
ENZYME->SUBSTRATE |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
LABELED -> NON-LABELED |
|
||
|
INHIBITOR -> TARGET |
|
||
|
DEGRADENT -> PARENT | |||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
RECOMBINANT ORGANISM->SUBSTRATE | |||
|
INHIBITOR -> TARGET | |||
|
DERIVATIVE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE -> PARENT |
|
||
|
|
METABOLITE -> PARENT |
|
||
|
|
PARENT -> METABOLITE |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
||
|
|
PARENT -> IMPURITY |
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
||
|
|
PARENT -> IMPURITY |
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|